{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380004053983238541.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"M Esteve"}],"foaf:familyName":[{"@value":"Esteve"}],"foaf:givenName":[{"@value":"M"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362825894374220928","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1136/gut.2004.040675"},{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/gut.2004.040675"}],"notation":[{"@value":"Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00535-010-0367-5_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ_SzkjKT4BaheuNYagAcwY2r3klp1"},{"@type":"CROSSREF","@value":"10.1038/nm.2811_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ_SzkjKT4BaheuNYagAcwY2r3klp1"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ_SzkjKT4BaheuNYagAcwY2r3klp1"},{"@type":"CROSSREF","@value":"10.1136/gut.2004.040675_SzkjKT4BaheuNYagAcwY2r3klp1"}]}